Chapter 54
Antihistamines, Antitussives, Decongestants, Expectorants, and Mucolytics
Antihistamines
Definition: Drugs that block the release or action of histamine, which is a chemical released during inflammation; this process increases secretions and narrows airways.
Categories:
First Generation: These antihistamines typically cause drowsiness. They display significant anticholinergic effects. Examples include:
Brompheniramine
Carbinoxamine
Chlorpheniramine
Clemastine
Cyproheptadine
Dexchlorpheniramine
Dimenhydrinate
Diphenhydramine
Hydroxyzine
Meclizine
Promethazine
Triprolidine
Second Generation: Nonsedating antihistamines with reduced sedative effects, although some may still cause drowsiness. Examples include:
Azelastine
Cetirizine
Desloratadine
Fexofenadine
Levocetirizine
Loratadine
Pharmacokinetics: Generally well absorbed orally with an onset of action of 1 to 3 hours; metabolized in the liver and excreted in feces and urine; cross the placenta and enter human milk.
Indications: Relieve symptoms of seasonal and perennial allergic rhinitis, allergic conjunctivitis, urticaria, angioedema.
Side Effects: Drowsiness, anticholinergic effects (dry mouth, dizziness, dysuria), arrhythmias, and potential QT interval prolongation leading to serious cardiac complications.
Contraindications: Caution during pregnancy/lactation.
Antitussives
Definition: Drugs that suppress the cough reflex, acting centrally on the brain or locally on the cough receptors in the respiratory tract.
Common examples include:
Benzonatate
Codeine
Dextromethorphan
Hydrocodone
Pharmacokinetics: Rapidly absorbed, liver metabolism, and urinary excretion; some pass through the placenta.
Indications: Used for unproductive coughs associated with various respiratory conditions (e.g., colds, pneumonia).
Considerations: Not suitable for patients who require a cough for airway clearance (e.g., after thoracic surgery).
Side Effects: CNS effects (drowsiness), gastrointestinal disturbances (nausea, constipation), and risk of respiratory depression.
Clinical Interactions: Avoid use with MAO inhibitors, narcotics with other sedatives, as they can exacerbate sedation risks.
Decongestants
Definition: Drugs causing local vasoconstriction to reduce blood flow to the upper respiratory tract, thus decreasing secretions.
Types:
Topical Nasal Decongestants:
Naphazoline
Oxymetazoline
Phenylephrine
Tetrahydrozoline
Xylometazoline
Oral Decongestants:
Phenylephrine
Pseudoephedrine (abused for meth production).
Steroid Nasal Decongestants:
Beclomethasone
Budesonide
Flunisolide
Fluticasone
Triamcinolone
Pharmacokinetics: Rapid onset with topical application; less systemic absorption.
Indications: Common cold, sinusitis, allergic rhinitis, otitis media pressure relief.
Adverse Effects: Rebound congestion (rhinitis medicamentosa) from prolonged use of topical agents; hypertension and other sympathomimetic effects.
Cautions: Patients with glaucoma, hypertension, or other chronic conditions should use with caution.
Expectorants
Definition: Drugs that increase productive cough to aid mucus clearance from the respiratory tract.
Example: Guaifenesin
Pharmacokinetics: Rapid absorption with peak effect in 30 minutes and duration of 4-6 hours.
Indications: Assist in clearing thickened secretions in respiratory conditions like bronchitis or pneumonia.
Side Effects: Include GI upset (nausea, vomiting) and potential allergic reactions (rash).
Contraindications: Not recommended for use longer than 1 week without seeking medical advice as this can mask important symptoms.
Mucolytics
Definition: Drugs that reduce the viscosity of mucus, making it easier to clear from the airways.
Examples include:
Acetylcysteine: Used for acetaminophen overdose and as a mucolytic.
Dornase alfa: Used to treat cystic fibrosis.
Pharmacokinetics: Administered via inhalation or intratracheally; acetylcysteine metabolized in the liver, both exert their effects primarily in the respiratory tract.
Indications: Used for chronic conditions characterized by thick mucus production, facilitating airway clearance.
Adverse Effects: Digestive upset, bronchospasm, rash; potential risk of anaphylaxis in sensitive individuals.
Cautions: Use with caution in patients with asthma due to risk of bronchospasm.
Summary of Key Considerations
Patient Education: Patients should be advised about the potential for interactions, the importance of reading labels on OTC products, and avoiding combining medications to prevent toxicity.
Professional Monitoring: Health professionals should assess treatment efficacy, monitor for adverse effects, adjust dosages as necessary, and provide thorough patient education regarding medication adherence and lifestyle modifications to support therapy.
Antihistamines
Definition: Drugs that act as histamine H1-receptor antagonists, blocking the binding of histamine to H1 receptors. This action prevents or reduces the effects of histamine release during inflammation, which typically includes increased vascular permeability, vasodilation, pruritus, and bronchoconstriction, leading to a reduction in secretions and narrowing of airways.
Categories:
First Generation: These antihistamines are lipophilic, readily cross the blood-brain barrier, and therefore typically cause significant central nervous system (CNS) depression (drowsiness, sedation). They also possess significant anticholinergic (muscarinic receptor blockade) effects, contributing to side effects like dry mouth, constipation, and urinary retention. Examples include:
Brompheniramine
Carbinoxamine
Chlorpheniramine
Clemastine
Cyproheptadine
Dexchlorpheniramine
Dimenhydrinate
Diphenhydramine (Benadryl)
Hydroxyzine
Meclizine
Promethazine
Triprolidine
Second Generation: These are less lipophilic and generally do not cross the blood-brain barrier to a significant extent, which results in reduced sedative effects compared to first-generation agents. While they are often termed "nonsedating," some individuals may still experience mild drowsiness. They also have minimal to no anticholinergic effects. Examples include:
Azelastine (nasal spray)
Cetirizine (Zyrtec)
Desloratadine (Clarinex)
Fexofenadine (Allegra)
Levocetirizine (Xyzal)
Loratadine (Claritin)
Pharmacokinetics: Generally well absorbed orally, with an onset of action ranging from 1 to 3 hours and a duration dependent on the specific drug (e.g., 4-6 hours for first-gen, 12-24 hours for second-gen). They are primarily metabolized in the liver by the cytochrome P450 (CYP) enzyme system and excreted in feces and urine. Many antihistamines, especially first-generation, can cross the placenta and enter human milk, necessitating caution during pregnancy and lactation.
Indications: Primarily used for the symptomatic relief of seasonal and perennial allergic rhinitis (hay fever), allergic conjunctivitis, acute and chronic urticaria (hives), angioedema, and other allergic reactions. First-generation antihistamines are also used for motion sickness, insomnia, and as antitussives due to their anticholinergic and sedative properties.
Side Effects:
First Generation: Drowsiness, sedation, impaired cognitive function, dizziness, fatigue, and significant anticholinergic effects such as dry mouth, blurred vision, urinary retention, and constipation. Cardiac effects can include arrhythmias and potential QT interval prolongation (particularly with promethazine or overdose) leading to serious cardiac complications.
Second Generation: Generally milder side effects, with less sedation, but some individuals may still experience a degree of drowsiness. Other potential side effects include headache, nausea, and dry mouth. Cardiac issues are much rarer.
Contraindications:
General: Hypersensitivity to the drug. Caution is advised during pregnancy/lactation, in elderly patients (increased susceptibility to anticholinergic effects), and in individuals with renal or hepatic impairment.
First Generation specific: Should be used with extreme caution or avoided in patients with narrow-angle glaucoma, benign prostatic hyperplasia (BPH) with urinary retention, bladder neck obstruction, pyloroduodenal obstruction, or symptomatic prostatic hypertrophy due to significant anticholinergic effects.
Antitussives
Definition: Drugs designed to suppress the cough reflex, primarily used for non-productive (dry) coughs that are irritating or prevent rest. They act either centrally on the cough center in the medulla oblongata or peripherally on cough receptors in the respiratory tract.
Common examples include:
Benzonatate (Tessalon Perles): Acts peripherally by anesthetizing the stretch receptors in the respiratory passages, lungs, and pleura.
Codeine: An opioid derivative that acts centrally to elevate the cough threshold. Classified as a Schedule II opioid, but often compounded as a Schedule V when in cough syrup formulations, due to lower opioid content. Has analgesic and sedative properties.
Dextromethorphan (DM): A non-opioid derivative that acts centrally by depressing the medullary cough center. It is structurally related to opioid analgesics but does not produce significant analgesia or physical dependence at therapeutic doses. However, abuse potential for its dissociative effects exists at high doses.
Hydrocodone: A more potent opioid than codeine, acting centrally to suppress cough. Classified as a Schedule II opioid and carries a higher risk of dependence and respiratory depression.
Pharmacokinetics: Antitussives are generally rapidly absorbed orally. They undergo significant liver metabolism via the CYP enzyme system (e.g., codeine is metabolized to morphine; dextromethorphan via CYP2D6) and are primarily excreted in the urine. Some agents, particularly opioid-derived ones, can pass through the placenta.
Indications: Used for the temporary relief of unproductive, dry coughs associated with various respiratory conditions such as the common cold, bronchitis, pharyngitis, laryngitis, and influenza, especially when the cough is bothersome or interferes with sleep.
Considerations: Antitussives are generally not suitable for patients with productive coughs, as suppressing a productive cough can lead to pooling of secretions, increasing the risk of infection and impairing airway clearance (e.g., after thoracic surgery, in chronic obstructive pulmonary disease (COPD) exacerbations, or cystic fibrosis).
Side Effects:
CNS effects: Drowsiness, sedation, dizziness, lightheadedness (especially with opioid-derived antitussives like codeine and hydrocodone).
Gastrointestinal disturbances: Nausea, vomiting, constipation.
Opioid-specific: Risk of respiratory depression (dose-dependent), dependence, and abuse potential (higher with codeine and hydrocodone). Elevated intracranial pressure is a concern for opioid antitussives.
Benzonatate: Drowsiness, dizziness, numbness in mouth/throat (if chewed), chest congestion, confusion.
Clinical Interactions: Avoid concomitant use with MAO inhibitors (can cause serotonin syndrome with dextromethorphan). Opioid and non-opioid antitussives (like dextromethorphan) should be used with caution when combined with other CNS depressants (e.g., alcohol, benzodiazepines, other sedatives) as they can exacerbate sedation and respiratory depression risks. Codeine and hydrocodone are contraindicated in children under 12 years and in some adolescents due to rapid metabolizer status for CYP2D6.
Decongestants
Definition: Sympathomimetic drugs that cause local vasoconstriction in the arterioles of the nasal mucosa, thereby reducing blood flow to the upper respiratory tract. This action decreases swelling of the nasal passages and leads to a reduction in secretions, alleviating nasal congestion.
Mechanism of Action: They primarily act as alpha-adrenergic agonists on the blood vessels in the nasal passages.
Types:
Topical Nasal Decongestants (alpha-adrenergic agonists): These are applied directly to the nasal mucosa, resulting in rapid onset and localized effects with minimal systemic absorption if used appropriately. Prolonged use can lead to adverse effects.
Naphazoline
Oxymetazoline (Afrin)
Phenylephrine (nasal spray)
Tetrahydrozoline
Xylometazoline
Oral Decongestants (systemic alpha/beta-adrenergic agonists): These are absorbed systemically and have broader effects but a slower onset of action. They are effective for both nasal and Eustachian tube congestion.
Phenylephrine (less effective orally than pseudoephedrine)
Pseudoephedrine (often abused for illicit methamphetamine production, leading to restricted access)
Steroid Nasal Decongestants (Corticosteroids): These reduce inflammation and swelling in the nasal passages through a different mechanism (anti-inflammatory action) and are used for allergic rhinitis rather than acute congestion from colds. They take several days to achieve full effect.
Beclomethasone
Budesonide
Flunisolide
Fluticasone
Triamcinolone
Pharmacokinetics:
Topical: Rapid onset (minutes) with a duration of action ranging from 4 to 12 hours depending on the agent. Minimal systemic absorption occurs if used as directed.
Oral: Slower onset (30 minutes to 1 hour) but longer duration of action. They are well absorbed orally, metabolized in the liver (some pseudoephedrine is excreted unchanged), and excreted renally.
Indications: Used for symptomatic relief of nasal congestion associated with the common cold, sinusitis, allergic rhinitis, and to relieve pressure in otitis media by decongesting the Eustachian tubes.
Adverse Effects:
Topical: The most significant adverse effect is rebound congestion (rhinitis medicamentosa), which occurs with prolonged use (typically >3-5 days). This phenomenon involves a cycle of congestion, overuse, and increasing congestion as the vasoconstrictor effect wears off, leading to dependence.
Oral: Due to systemic absorption, they can cause sympathomimetic effects. These include hypertension, tachycardia, palpitations, central nervous system stimulation (nervousness, restlessness, insomnia, anxiety, tremors), and headache. Pseudoephedrine has a higher incidence of these systemic effects than oral phenylephrine.
Cautions: Decongestants, especially oral forms and sustained topical use, should be used with extreme caution or are contraindicated in patients with conditions sensitive to adrenergic stimulation. These include glaucoma (can increase intraocular pressure), hypertension (can elevate blood pressure), severe cardiovascular disease (angina, arrhythmias, history of myocardial infarction), hyperthyroidism (exacerbate tremors, tachycardia), diabetes mellitus (can increase blood glucose), and prostatic hypertrophy (exacerbate urinary retention). Combination with MAO inhibitors can lead to a hypertensive crisis.
Expectorants
Definition: Drugs that work by increasing productive coughs to aid in the clearance of mucus and secretions from the respiratory tract. They are thought to achieve this by thinning respiratory secretions, making them easier to expel.
Example:
Guaifenesin: The most common expectorant, available in many over-the-counter cough and cold preparations. It is believed to work by irritating the gastric mucosa, which then stimulates vagal nerve afferents, triggering a parasympathetic reflex that increases respiratory tract fluid secretion, thereby thinning mucus and making it less viscous and easier to clear, leading to a more productive cough.
Pharmacokinetics: Guaifenesin is rapidly absorbed orally, with a peak effect typically occurring within 30 minutes and a duration of action of approximately 4-6 hours. It undergoes metabolism in the liver (rapid hydrolysis) and is primarily excreted in the urine as inactive metabolites.
Indications: Used to assist in clearing thickened secretions and promoting a productive cough in various acute and chronic respiratory conditions where tenacious mucus is a problem. These include the common cold, bronchitis, pharyngitis, laryngitis, influenza, sinusitis, and persistent coughs related to these conditions.
Side Effects: Generally well-tolerated. Side effects may include gastrointestinal upset (nausea, vomiting, diarrhea, stomach pain), headache, dizziness, and potential allergic reactions (skin rash, urticaria).
Contraindications: Hypersensitivity to guaifenesin. It is generally not recommended for use longer than 1 week for cough associated with upper respiratory infections without seeking medical advice, as this can mask underlying serious symptoms or conditions that require specific treatment. Not recommended for children under 4 years of age without medical supervision.
Mucolytics
Definition: Drugs that directly reduce the viscosity of mucus (thickeness), making it less tenacious and easier to clear from the airways through coughing or suctioning. They work by breaking down the chemical bonds within the mucus.
Examples include:
Acetylcysteine: This drug works by disrupting the disulfide bonds in mucoproteins, which reduces the viscosity of respiratory secretions. It is administered via nebulization or direct instillation. Besides its mucolytic action, acetylcysteine is also a crucial antidote for acetaminophen overdose; in this context, it acts as a precursor to glutathione, replenishing hepatic glutathione stores and protecting against hepatotoxicity.
Dornase alfa (Pulmozyme): A recombinant human deoxyribonuclease I (rhDNase) that selectively cleaves extracellular DNA present in high concentrations in the purulent sputum of cystic fibrosis patients. This DNA contributes significantly to the viscosity of the mucus, and its enzymatic breakdown reduces sputum thickness.
Pharmacokinetics:
Acetylcysteine: Administered primarily via inhalation (nebulizer) or directly into the trachea. When used for acetaminophen overdose, it is given orally or intravenously. It is metabolized in the liver by deacetylation. Its mucolytic effects are local within the respiratory tract.
Dornase alfa: Administered via inhalation using a nebulizer. It acts locally within the airways and has minimal systemic absorption or effects.
Indications: Used for chronic conditions characterized by thick, tenacious mucus production, facilitating airway clearance and improving respiratory function.
Acetylcysteine: Primarily for conditions like cystic fibrosis, chronic bronchitis, emphysema, atelectasis due to mucous plug, and during diagnostic bronchoscopy. It is also essential for treating acetaminophen overdose.
Dornase alfa: Specifically indicated for the management of cystic fibrosis in conjunction with standard therapies to improve lung function and reduce the frequency of respiratory infections.
Adverse Effects:
Acetylcysteine: Can cause digestive upset (nausea, vomiting) due to its unpleasant smell (rotten egg odor), bronchospasm (especially in asthmatics), stomatitis, rhinitis, and rarely, rash. In overdose treatment, it can cause flushing, itching, and anaphylactoid reactions.
Dornase alfa: Common side effects include pharyngitis, voice alteration (hoarseness), rash, chest pain, and conjunctivitis. Bronchospasm is a less common but possible adverse effect.
Cautions:
Acetylcysteine: Use with extreme caution in patients with asthma or other obstructive airway diseases due to the risk of inducing or exacerbating bronchospasm. Patients should be monitored for airway obstruction.
Dornase alfa: Hypersensitivity reactions are possible. The safety and efficacy in children under years of age for cystic fibrosis are less established.
Summary of Key Considerations
Patient Education: Patients should be advised about the potential for drug-drug interactions (especially with OTC products), the importance of reading labels on over-the-counter (OTC) products, and avoiding combining multiple medications with similar active ingredients to prevent accidental overdose or toxicity. Specific instructions on proper administration (e.g., nebulizer use, topical nasal spray technique), duration of use, and recognition of adverse effects are crucial. They should also be educated on when to seek medical advice (e.g., persistent cough, worsening symptoms, severe side effects).
Professional Monitoring: Health professionals should regularly assess treatment efficacy (e.g., symptom relief, improved breathing parameters), monitor closely for adverse effects, adjust dosages as necessary based on patient response and tolerability, and provide thorough patient education regarding medication adherence, potential side effects, and relevant lifestyle modifications (e.g., adequate hydration for expectorants, avoiding irritants for allergic rhinitis) to support optimal therapy.
Antihistamines
Definition: Drugs that act as histamine H1-receptor antagonists, blocking the binding of histamine to H1 receptors. This action prevents or reduces the effects of histamine release during inflammation, which typically includes increased vascular permeability, vasodilation, pruritus, and bronchoconstriction, leading to a reduction in secretions and narrowing of airways.
Categories:
First Generation: These antihistamines are lipophilic, readily cross the blood-brain barrier, and therefore typically cause significant central nervous system (CNS) depression (drowsiness, sedation). They also possess significant anticholinergic (muscarinic receptor blockade) effects, contributing to side effects like dry mouth, constipation, and urinary retention. Examples include:
Brompheniramine
Carbinoxamine
Chlorpheniramine
Clemastine
Cyproheptadine
Dexchlorpheniramine
Dimenhydrinate
Diphenhydramine (Benadryl)
Hydroxyzine
Meclizine
Promethazine
Triprolidine
Second Generation: These are less lipophilic and generally do not cross the blood-brain barrier to a significant extent, which results in reduced sedative effects compared to first-generation agents. While they are often termed "nonsedating," some individuals may still experience mild drowsiness. They also have minimal to no anticholinergic effects. Examples include:
Azelastine (nasal spray)
Cetirizine (Zyrtec)
Desloratadine (Clarinex)
Fexofenadine (Allegra)
Levocetirizine (Xyzal)
Loratadine (Claritin)
Pharmacokinetics: Generally well absorbed orally, with an onset of action ranging from 1 to 3 hours and a duration dependent on the specific drug (e.g., 4-6 hours for first-gen, 12-24 hours for second-gen). They are primarily metabolized in the liver by the cytochrome P450 (CYP) enzyme system and excreted in feces and urine. Many antihistamines, especially first-generation, can cross the placenta and enter human milk, necessitating caution during pregnancy and lactation.
Indications: Primarily used for the symptomatic relief of seasonal and perennial allergic rhinitis (hay fever), allergic conjunctivitis, acute and chronic urticaria (hives), angioedema, and other allergic reactions. First-generation antihistamines are also used for motion sickness, insomnia, and as antitussives due to their anticholinergic and sedative properties.
Side Effects:
First Generation: Drowsiness, sedation, impaired cognitive function, dizziness, fatigue, and significant anticholinergic effects such as dry mouth, blurred vision, urinary retention, and constipation. Cardiac effects can include arrhythmias and potential QT interval prolongation (particularly with promethazine or overdose) leading to serious cardiac complications.
Second Generation: Generally milder side effects, with less sedation, but some individuals may still experience a degree of drowsiness. Other potential side effects include headache, nausea, and dry mouth. Cardiac issues are much rarer.
Contraindications:
General: Hypersensitivity to the drug. Caution is advised during pregnancy/lactation, in elderly patients (increased susceptibility to anticholinergic effects), and in individuals with renal or hepatic impairment.
First Generation specific: Should be used with extreme caution or avoided in patients with narrow-angle glaucoma, benign prostatic hyperplasia (BPH) with urinary retention, bladder neck obstruction, pyloroduodenal obstruction, or symptomatic prostatic hypertrophy due to significant anticholinergic effects.
Antitussives
Definition: Drugs designed to suppress the cough reflex, primarily used for non-productive (dry) coughs that are irritating or prevent rest. They act either centrally on the cough center in the medulla oblongata or peripherally on cough receptors in the respiratory tract.
Common examples include:
Benzonatate (Tessalon Perles): Acts peripherally by anesthetizing the stretch receptors in the respiratory passages, lungs, and pleura.
Codeine: An opioid derivative that acts centrally to elevate the cough threshold. Classified as a Schedule II opioid, but often compounded as a Schedule V when in cough syrup formulations, due to lower opioid content. Has analgesic and sedative properties.
Dextromethorphan (DM): A non-opioid derivative that acts centrally by depressing the medullary cough center. It is structurally related to opioid analgesics but does not produce significant analgesia or physical dependence at therapeutic doses. However, abuse potential for its dissociative effects exists at high doses.
Hydrocodone: A more potent opioid than codeine, acting centrally to suppress cough. Classified as a Schedule II opioid and carries a higher risk of dependence and respiratory depression.
Pharmacokinetics: Antitussives are generally rapidly absorbed orally. They undergo significant liver metabolism via the CYP enzyme system (e.g., codeine is metabolized to morphine; dextromethorphan via CYP2D6) and are primarily excreted in the urine. Some agents, particularly opioid-derived ones, can pass through the placenta.
Indications: Used for the temporary relief of unproductive, dry coughs associated with various respiratory conditions such as the common cold, bronchitis, pharyngitis, laryngitis, and influenza, especially when the cough is bothersome or interferes with sleep.
Considerations: Antitussives are generally not suitable for patients with productive coughs, as suppressing a productive cough can lead to pooling of secretions, increasing the risk of infection and impairing airway clearance (e.g., after thoracic surgery, in chronic obstructive pulmonary disease (COPD) exacerbations, or cystic fibrosis).
Side Effects:
CNS effects: Drowsiness, sedation, dizziness, lightheadedness (especially with opioid-derived antitussives like codeine and hydrocodone).
Gastrointestinal disturbances: Nausea, vomiting, constipation.
Opioid-specific: Risk of respiratory depression (dose-dependent), dependence, and abuse potential (higher with codeine and hydrocodone). Elevated intracranial pressure is a concern for opioid antitussives.
Benzonatate: Drowsiness, dizziness, numbness in mouth/throat (if chewed), chest congestion, confusion.
Clinical Interactions: Avoid concomitant use with MAO inhibitors (can cause serotonin syndrome with dextromethorphan). Opioid and non-opioid antitussives (like dextromethorphan) should be used with caution when combined with other CNS depressants (e.g., alcohol, benzodiazepines, other sedatives) as they can exacerbate sedation and respiratory depression risks. Codeine and hydrocodone are contraindicated in children under 12 years and in some adolescents due to rapid metabolizer status for CYP2D6.
Decongestants
Definition: Sympathomimetic drugs that cause local vasoconstriction in the arterioles of the nasal mucosa, thereby reducing blood flow to the upper respiratory tract. This action decreases swelling of the nasal passages and leads to a reduction in secretions, alleviating nasal congestion.
Mechanism of Action: They primarily act as alpha-adrenergic agonists on the blood vessels in the nasal passages.
Types:
Topical Nasal Decongestants (alpha-adrenergic agonists): These are applied directly to the nasal mucosa, resulting in rapid onset and localized effects with minimal systemic absorption if used appropriately. Prolonged use can lead to adverse effects.
Naphazoline
Oxymetazoline (Afrin)
Phenylephrine (nasal spray)
Tetrahydrozoline
Xylometazoline
Oral Decongestants (systemic alpha/beta-adrenergic agonists): These are absorbed systemically and have broader effects but a slower onset of action. They are effective for both nasal and Eustachian tube congestion.
Phenylephrine (less effective orally than pseudoephedrine)
Pseudoephedrine (often abused for illicit methamphetamine production, leading to restricted access)
Steroid Nasal Decongestants (Corticosteroids): These reduce inflammation and swelling in the nasal passages through a different mechanism (anti-inflammatory action) and are used for allergic rhinitis rather than acute congestion from colds. They take several days to achieve full effect.
Beclomethasone
Budesonide
Flunisolide
Fluticasone
Triamcinolone
Pharmacokinetics:
Topical: Rapid onset (minutes) with a duration of action ranging from 4 to 12 hours depending on the agent. Minimal systemic absorption occurs if used as directed.
Oral: Slower onset (30 minutes to 1 hour) but longer duration of action. They are well absorbed orally, metabolized in the liver (some pseudoephedrine is excreted unchanged), and excreted renally.
Indications: Used for symptomatic relief of nasal congestion associated with the common cold, sinusitis, allergic rhinitis, and to relieve pressure in otitis media by decongesting the Eustachian tubes.
Adverse Effects:
Topical: The most significant adverse effect is rebound congestion (rhinitis medicamentosa), which occurs with prolonged use (typically >3-5 days). This phenomenon involves a cycle of congestion, overuse, and increasing congestion as the vasoconstrictor effect wears off, leading to dependence.
Oral: Due to systemic absorption, they can cause sympathomimetic effects. These include hypertension, tachycardia, palpitations, central nervous system stimulation (nervousness, restlessness, insomnia, anxiety, tremors), and headache. Pseudoephedrine has a higher incidence of these systemic effects than oral phenylephrine.
Cautions: Decongestants, especially oral forms and sustained topical use, should be used with extreme caution or are contraindicated in patients with conditions sensitive to adrenergic stimulation. These include glaucoma (can increase intraocular pressure), hypertension (can elevate blood pressure), severe cardiovascular disease (angina, arrhythmias, history of myocardial infarction), hyperthyroidism (exacerbate tremors, tachycardia), diabetes mellitus (can increase blood glucose), and prostatic hypertrophy (exacerbate urinary retention). Combination with MAO inhibitors can lead to a hypertensive crisis.
Expectorants
Definition: Drugs that work by increasing productive coughs to aid in the clearance of mucus and secretions from the respiratory tract. They are thought to achieve this by thinning respiratory secretions, making them easier to expel.
Example:
Guaifenesin: The most common expectorant, available in many over-the-counter cough and cold preparations. It is believed to work by irritating the gastric mucosa, which then stimulates vagal nerve afferents, triggering a parasympathetic reflex that increases respiratory tract fluid secretion, thereby thinning mucus and making it less viscous and easier to clear, leading to a more productive cough.
Pharmacokinetics: Guaifenesin is rapidly absorbed orally, with a peak effect typically occurring within 30 minutes and a duration of action of approximately 4-6 hours. It undergoes metabolism in the liver (rapid hydrolysis) and is primarily excreted in the urine as inactive metabolites.
Indications: Used to assist in clearing thickened secretions and promoting a productive cough in various acute and chronic respiratory conditions where tenacious mucus is a problem. These include the common cold, bronchitis, pharyngitis, laryngitis, influenza, sinusitis, and persistent coughs related to these conditions.
Side Effects: Generally well-tolerated. Side effects may include gastrointestinal upset (nausea, vomiting, diarrhea, stomach pain), headache, dizziness, and potential allergic reactions (skin rash, urticaria).
Contraindications: Hypersensitivity to guaifenesin. It is generally not recommended for use longer than 1 week for cough associated with upper respiratory infections without seeking medical advice, as this can mask underlying serious symptoms or conditions that require specific treatment. Not recommended for children under 4 years of age without medical supervision.
Mucolytics
Definition: Drugs that directly reduce the viscosity of mucus (thickeness), making it less tenacious and easier to clear from the airways through coughing or suctioning. They work by breaking down the chemical bonds within the mucus.
Examples include:
Acetylcysteine: This drug works by disrupting the disulfide bonds in mucoproteins, which reduces the viscosity of respiratory secretions. It is administered via nebulization or direct instillation. Besides its mucolytic action, acetylcysteine is also a crucial antidote for acetaminophen overdmse; in this context, it acts as a precursor to glutathione, replenishing hepatic glutathione stores and protecting against hepatotoxicity.
Dornase alfa (Pulmozyme): A recombinant human deoxyribonuclease I (rhDNase) that selectively cleaves extracellular DNA present in high concentrations in the purulent sputum of cystic fibrosis patients. This DNA contributes significantly to the viscosity of the mucus, and its enzymatic breakdown reduces sputum thickness.
Pharmacokinetics:
Acetylcysteine: Administered primarily via inhalation (nebulizer) or directly into the trachea. When used for acetaminophen overdose, it is given orally or intravenously. It is metabolized in the liver by deacetylation. Its mucolytic effects are local within the respiratory tract.
Dornase alfa: Administered via inhalation using a nebulizer. It acts locally within the airways and has minimal systemic absorption or effects.
Indications: Used for chronic conditions characterized by thick, tenacious mucus production, facilitating airway clearance and improving respiratory function.
Acetylcysteine: Primarily for conditions like cystic fibrosis, chronic bronchitis, emphysema, atelectasis due to mucous plug, and during diagnostic bronchoscopy. It is also essential for treating acetaminophen overdose.
Dornase alfa: Specifically indicated for the management of cystic fibrosis in conjunction with standard therapies to improve lung function and reduce the frequency of respiratory infections.
Adverse Effects:
Acetylcysteine: Can cause digestive upset (nausea, vomiting) due to its unpleasant smell (rotten egg odor), bronchospasm (especially in asthmatics), stomatitis, rhinitis, and rarely, rash. In overdose treatment, it can cause flushing, itching, and anaphylactoid reactions.
Dornase alfa: Common side effects include pharyngitis, voice alteration (hoarseness), rash, chest pain, and conjunctivitis. Bronchospasm is a less common but possible adverse effect.
Cautions:
Acetylcysteine: Use with extreme caution in patients with asthma or other obstructive airway diseases due to the risk of inducing or exacerbating bronchospasm. Patients should be monitored for airway obstruction.
Dornase alfa: Hypersensitivity reactions are possible. The safety and efficacy in children under years of age for cystic fibrosis are less established.
Summary of Key Considerations
Patient Education: Patients should be advised about the potential for drug-drug interactions (especially with OTC products), the importance of reading labels on over-the-counter (OTC) products, and avoiding combining multiple medications with similar active ingredients to prevent accidental overdose or toxicity. Specific instructions on proper administration (e.g., nebulizer use, topical nasal spray technique), duration of use, and recognition of adverse effects are crucial. They should also be educated on when to seek medical advice (e.g., persistent cough, worsening symptoms, severe side effects).
Professional Monitoring: Health professionals should regularly assess treatment efficacy (e.g., symptom relief, improved breathing parameters), monitor closely for adverse effects, adjust dosages as necessary based on patient response and tolerability, and provide thorough patient education regarding medication adherence, potential side effects, and relevant lifestyle modifications (e.g., adequate hydration for expectorants, avoiding irritants for allergic rhinitis) to support optimal therapy.